A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
ISONIAZID-INDUCED LIVER INJURY: PHARMACOGENETIC ASPECTS
Russian Journal for Personalized Medicine
Inter-individual differences in anti-tuberculosis chemotherapy outcomes have been demonstrated in clinical practice, such as, achievement of intended therapeutic effect in some patients, and insufficiency or absence of response to treatment in others, with development of adverse drug reactions, especially, isoniazid-induced liver injury. Isoniazid-induced liver injuries are the main reason for isoniazid discontinuation, which further leads to considerably reduced effectiveness ofdoi:10.18705/2782-3806-2022-2-3-38-46 fatcat:nzvgo5ytgrhyrbvaed4pikupji